The association between estrogen receptor 2 gene polymorphism and complexity of coronary artery disease: an analysis in elective percutaneous coronary intervention patients

Farzaneh Foroughinia1*, Pooyan Dehghani2, Mehdi Dianatpour3,4, Arghavan Amiri5, Iman Jamhiri3 and Parisa Ghasemiyeh1*

Abstract

Background: One of the most common causes of death in the world is coronary artery disease (CAD). Estrogen, the most important early sex hormones in women, plays an important role in the risk reduction of cardiovascular disease (CVD). Expression of estrogen as well as its receptors including estrogen receptor alpha (ER1) and estrogen receptor beta (ER2) might have an association with the severity or the complexity of CAD. Since most articles have focused on the relationship between ER1 gene polymorphism and CAD, in this study, we aimed to evaluate the association of two ER2 gene polymorphisms, rs4986938 (AluI) and rs1256049 (RsaI), with the severity of CAD.

Methods: 148 patients with confirmed CAD who underwent elective percutaneous coronary intervention (PCI) were included in this study. Blood samples were collected before coronary angiography and ER2 gene polymorphisms were analyzed by the PCR–RFLP method. The STNTAX Score (SS), grading system for CAD complexity, was evaluated by an interventional cardiologist who was blinded to other data.

Results: 110 men and 38 women were participated in this study. Our results revealed a statistically significant relationship between SS and rs4986938 polymorphism of ER2 in men. In contrast, there was no association between rs1256049 genotypes and SS after performing regression analysis.

Conclusions: Besides to the estrogen level, the genetic variation of its receptors might play an important role in the severity or the complexity of CAD. According to our results, rs4986938 polymorphism of ER2 gene may assert a pivotal role in the severity of CAD in men; however, this assumption needs to be proved in studies with a larger population.

Keywords: Cardiovascular disease, Estrogen receptor Beta, Polymorphism, SYNTAX score

Background

Cardiovascular disease (CVD) is considered as one of the major causes of death worldwide. Coronary artery disease (CAD) and cerebrovascular diseases are among the most common causes of deaths due to CVD [1]. According to the epidemiologic studies, premenopausal women have less risk for CVD in comparison with men with the
same age that may be because of the protective effects of estrogen in the prevention of CVD [2]. Estrogen can serve its effect by binding to estrogen receptor α (ER1), estrogen receptor β (ER2), and G-protein-coupled estrogen receptor 30 (GPR30). The possible protective mechanism of estrogen against CVD would be related to its effect on angiogenesis, fibrosis, vascular function, and oxidative stress processes [3].

Estrogen could induce its cardioprotective effects through a receptor-based biological mechanism. Recent researches revealed that genetic variants have an important role in cardio- and cerbro-vascular diseases. For instance, ER1 is an important indicator of atheroprotective effect of estrogen on cardiovascular system. [4]. A study evaluated the association between ER1 single nucleotide polymorphism (SNP) and Intima-media thickness (IMT) in carotid artery, an important predictor of CVD, demonstrated a significant association between rs2228480 and rs3798758 with the IMT of carotid artery in Taiwanese women [5]. A case-cohort design on evaluation of the relationship between ER1 SNP and the risk of coronary heart disease (CHD) and stroke in Finnish population, revealed the significant association of rs2334693 polymorphism with the higher risk of CHD in men but not with ischemic stroke [6]. In addition, a significant association between ER1 gene polymorphism and low density lipoprotein (LDL) metabolism, an important predictor of atherosclerosis and CVD, was found in women [7]. Arterial stiffness enhancement and increased wave reflection are the other risk factors for CVD. It has been hypothesized that there is an association between arterial stiffness and genetic variance of ER1, ER2, and CYP19A1 (aromatase). Results of the American population study showed a strong relation between ER1 and ER2 gene polymorphisms and enhanced wave reflection but it is failed to show any association respected to CYP19A1 [8]. An additional table shows these studies in more detail [see Additional file 1].

The SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score (SS) is an angiographic tool using to predict the coronary vasculature characteristics based on the number of lesions and also their complexity, location, and function. SS would be calculated through a computer program using 12 main questions which are about the dominance, number of lesions, segments involved per lesion, total occlusion, trifurcation, bifurcation, aorto-ostial lesion, severe tortuosity, length > 20 mm, heavy calcification, thrombus, and diffuse disease/small vessels. Higher SS would be a predictor of higher level of disease complexity, more challenging pharmacotherapy, and worse prognosis following coronary intervention [9].

Since most of studies have focused on ER1 and few papers have evaluated the role of ER2 in atherosclerotic diseases, in this study, we aimed to evaluate the association between two major SNPs of ER2 gene containing rs4986938 (Alul) and rs1256049 (Rsal) and the severity and the complexity of CAD expressed as SS.

**Methods**

The study protocol was assessed and approved by the Ethics Committee of Shiraz University of Medical Sciences (SUMS, Iran) (No: IR.SUMS.REC.1397.369). Written consent form and permission for DNA analyses was obtained from all participants.

**Subjects**

Of 200 patients, admitted to two tertiary care hospitals of SUMS (Ghalb-Al-Zahra and Nemazee hospitals) with the diagnosis of CAD from August 2018 to February 2019, 148 participants were recruited to the study (fifty-two patients were excluded due to lack of data and refusal to sign the consent form).

Inclusion criteria were age of 32–80 years old and confirmed diagnosis of CAD (> 50% luminal stenosis in at least one major coronary artery in angiography). Exclusion criteria include consumption of oral contraceptives and hormone replacement therapy during one month prior to the study, familial hypercholesterolemia, malignancy, schizophrenia, connective tissue disease, or chronic inflammatory diseases.

Patients who fulfilled the criteria were included into this project. Demographic and clinical data were documented for each patient according to the patients’ hospital record.

**Coronary angiography**

Patients who were candidates for invasive strategy with coronary angiography were enrolled into the study. Patients received Aspirin, clopidogrel, and anticoagulation according to current guidelines prior to coronary angiography (aspirin, 325 mg loading dose and then 80 mg/d for the rest of their life and clopidogrel, 600 mg loading dose and then 75 mg/d for at least one year after PCI as well as weight-adjusted intravenous heparin with a target activated clotting time of 250–350 Sec before PCI [10]. Procedure was performed with local anesthesia and via radial or femoral approaches [11]. Ultravist® or Visipaque® was used as contrast agents.

Subjects with > 50% stenosis in at least one major epicardial artery greater than 1.5 mm were included into the study. Coronary angiographic data, including vessels’ involvement, percentage of stenosis and SS were evaluated by an interventional cardiologist who was blinded to other data. SS was calculated using the official calculator from the SYNTAX score website [12].
The final plan of the management for patients was varied from medical therapy (11%) to percutaneous coronary intervention (PCI) (67%) and coronary artery bypass grafting in the remaining (22%).

Severe CAD is defined as ≥70% luminal stenosis in one major epicardial vessel or ≥50% stenosis in the left main coronary artery (LMD) and Multivessel disease (MVD) is defined as more than one coronary artery involvement with ≥70% stenosis [13, 14]. Patients were categorized into two groups according to the SYNTAX score: low risk (SS < 23) and intermediate/high risk (SS ≥ 23) [15].

Biological samples and genotyping

In order to assess ER2 gene polymorphisms, blood samples were collected in the EDTA vacutainer tubes from all patients. Whole blood was stored at −20 °C freezer until use. Genomic DNA for PCR was extracted from whole blood by DNA extraction kit (Yekta tajhiz, Iran) according to the manufacturer protocol.

Selected regions of ER2 gene were amplified by polymerase chain reaction (PCR) using specific primers listed in Table 1. All primers, used for the amplification of rs1256049 and rs4986938 polymorphisms regions in ER2 gene, were designed by the Primer 3 software and were obtained from metabiop (metabion international AG, Martinsread, Germany). The reaction program for rs1256049 and rs4986938 polymorphisms amplification was as follows: initial denaturation for 4 min at 94°C, followed by 35 cycles of 94°C for 30 s, 66°C for 30 s, 72°C for 30 s and final elongation at 72°C for 7 min. The PCR reactions were performed in Veriti Thermal Cycler (Applied Biosystems, Foster City, CA, USA).

For RFLP, the PCR products of rs1256049 and rs4986938 polymorphisms were digested with Rsal (#ER1121, 5U at 37 °C for 16 h) and Alul (#ER0011, 5U at 37 °C for 16 h) (Fermentas), respectively. DNA fragments from RFLP were electrophoresed on 2% agarose gel to determine the rs1256049 and rs4986938 polymorphic patterns.

Table 1

| Gene                | Sequence                 | Band size (fragments obtained after digestion) |
|---------------------|--------------------------|-----------------------------------------------|
| rs1256049 Forward   | TTCGTAGCCGGAGGTCTAGT      | 582 bp (A: 293 bp + 289 bp; G: 582 bp)         |
| rs1256049 Reverse   | TGAACCTTGGACCCAACTC       | 646 bp (A: 445 bp + 201 bp; G: 646 bp)         |
| rs4986938 Forward   | GTGGTGGTGCGAGACACAGAG     |                                               |
| rs4986938 Reverse   | AGGCCCAGTAGGTGGAAAC       |                                               |

Statistical analysis

Collected information of this study was analyzed using Statistical Package for Social Sciences (SPSS) for Windows software (version 16, Chicago, USA). All continuous variables were reported as the mean [standard deviation (SD)] and the differences between men and women were analyzed by independent samples t test. Categorical variables were showed as absolute number and percentages and were tested using chi-square test.

For comparison between ER2 genotypes and allele frequencies and SS or sex, chi-square test and Fisher’s exact test were applied. Multiple linear regression analysis was performed to assess the association between SS and conventional cardiovascular risk factors as well as investigated ER2 genotypes by genders.

Results

Totally, 148 patients were enrolled into the study. The mean age of all patients was 59.06 (11.42). 110 (74.7%) men with the mean age of 57.62 (11.75) and 38 (25.3%) women with the mean age of 63.29 (9.28) were participated in our study.

Clinical baseline characteristics of patients were described in Table 2, dividing participants in two groups according to the sex. Both groups were similar in all variables with the exception of age (p = 0.01), glomerular filtration rate (GFR) (p < 0.001), frequency of hypertension (p = 0.02), diabetes mellitus (DM) (p = 0.01), and active smoking (p = 0.001). In addition, no significant difference was found between sex and endpoints such as SS, severe CAD, and the number of diseased vessels. The distribution of SS in studied patients was reported in the supplementary file [see Additional file 2].

All samples were examined for ER2 gene polymorphisms (rs1256049 and rs4986938). The gel electrophoresis results after enzymatic digestion are shown in Fig. 1. Of 148 samples analyzed for rs1256049 polymorphism, a statistically significant relationship was found between SS and rs1256049 genotypes of ER2 gene (p = 0.01) but not with ss1256049 alleles (p = 0.05). Of note, AG genotype was found to be the more prevalent ones in patients with SS ≥ 23. In contrast, there was no association between rs4986938 genotypes and alleles and SS. The same results...
### Table 2: Patients' demographic and clinical characteristics

| Variables                                      | Total (n = 148) | Men (n = 110) | Women (n = 38) | p value |
|------------------------------------------------|-----------------|---------------|----------------|---------|
| Age, years, mean (SD)                         | 59.06 (11.42)   | 57.62 (11.75) | 63.29 (9.28)   | 0.01    |
| DM, N (%)                                      | 60 (40)         | 3 (33.6)      | 22 (57.9)      | 0.01    |
| Hyperlipidemia, N (%)                         | 68 (45.3)       | 46 (41.8)     | 21 (55.3)      | 0.15    |
| Hypertension, N (%)                           | 74 (49.3)       | 48 (43.6)     | 25 (35.8)      | 0.02    |
| Current smoker, N (%)                         | 68 (45.3)       | 64 (57.1)     | 4 (10.5)       | < 0.001 |
| Previous MI, N (%)                            | 6 (4)           | 5 (4.5)       | 1 (2.6)        | NA      |
| BB-treated, N (%)                             | 109 (72.7)      | 80 (71.4)     | 29 (76.3)      | 0.66    |
| Statin-treated, N (%)                         | 136 (91.1)      | 102 (92.7)    | 34 (89.5)      | 0.50*   |
| ACE inhibitor-treated, N (%)                  | 93 (62)         | 68 (60.7)     | 25 (65.8)      | 0.66    |
| GFR (MDRD), ml/min/1.73m², mean (SD)          | 77.16 (20.28)   | 81.41 (18.79) | 64.61 (19.53)  | < 0.001 |
| Creatinine, mg/dL, mean (SD)                  | 1.04 (0.22)     | 1.06 (0.21)   | 1.00 (0.25)    | 0.12    |
| BUN, mg/dL, mean (SD)                         | 16.31 (6.38)    | 15.86 (5.22)  | 17.64 (8.9)    | 0.15    |
| SYNTAX Score, mean (SD)                       | 18.61 (11.85)   | 17.86 (10.85) | 19.79 (13.76)  | 0.38    |
| SYNTAX Score, N (%)                           |                 |               |                |         |
| ≥ 23                                          | 41 (27.3)       | 28 (25)       | 13 (34.2)      | 0.20    |
| < 23                                          | 109 (72.7)      | 84 (75)       | 25 (65.8)      |         |
| Severe CAD, N (%)                             | 122 (82.4)      | 90 (81.1)     | 32 (84.2)      | 0.74    |
| Diseased vessel, N (%)                        |                 |               |                |         |
| One vessel                                    | 51 (34.5)       | 36 (33)       | 15 (39.5)      |         |
| Two vessel                                    | 56 (37.8)       | 44 (40.4)     | 12 (31.6)      | 0.66    |
| Three vessel                                  | 40 (27)         | 29 (26.6)     | 11 (28.9)      |         |
| MVD, N (%)                                    | 74 (50)         | 56 (50.9)     | 18 (47.4)      | 0.71    |

DM: diabetes mellitus, MI: myocardial infarction, BB: beta blocker, ACEI: Angiotensin converting enzyme inhibitor, GFR: glomerular filtration rate, BUN: blood urea nitrogen, CAD: coronary artery disease, MVD: multi-vessel disease

*p values are from χ² test

---

**Fig. 1** The gel electrophoresis results after enzymatic digestion. **A** Genotypes of rs1256049 polymorphisms. **B** Genotypes of rs4986938 polymorphisms. 100 bp ladder used. Full-length blots/gels are presented in Supplementary Figures [see Additional files 3 and 4]
were reported for the association between sex and rs1256049 and rs4986938 polymorphisms of ER2 gene (Table 3).

According to the regression analysis, none of rs1256049 genotypes were associated with SS in both genders. Regarding rs4986938 polymorphism, there was a relationship between GG genotype and SS as well as AG genotype and SS in men; in contrast, no relationship was found in women. Table 4 presents cardiovascular risk factors and ER2 gene polymorphisms associated with SS by gender.

Table 3  Associations of sex and SYNTAX score with ER2 gene polymorphisms in patients with CAD

| Receptor gene | SYNTAX score | Gender | p value |
|---------------|--------------|--------|---------|
|               | ˂ 23 (n = 109) | ≥ 23 (n = 41) | | | Men (n = 110) | Women (n = 38) | p value |
| rs4986938, N (%) | | | | | | |
| GG | 58 (53.2) | 25 (61) | 0.16 | 61 (54.5) | 22 (57.9) | 0.9 |
| AG | 37 (33.9) | 15 (36.6) | 40 (35.7) | 12 (31.6) |
| AA | 14 (12.8) | 1 (2.4) | 11 (9.8) | 4 (10.5) |
| Alleles, N (%) | | | | | | |
| A | 63 (28.9) | 19 (23.2) | 0.32 | 64 (28.6) | 18 (23.7) | 0.41 |
| G | 155 (71.1) | 63 (76.8) | 160 (71.4) | 58 (76.3) |
| rs1256049, N (%) | | | | | | |
| GG | 101 (92.7) | 32 (78) | 0.01 | 98 (87.5) | 35 (92.1) | 0.82* |
| AG | 7 (6.4) | 9 (22) | 13 (11.6) | 3 (7.9) |
| AA | 1 (0.9) | 0 (0) | 1 (0.9) | 0 (0) |
| Alleles, N (%) | | | | | | |
| A | 9 (4.1) | 9 (11) | 0.05 | 15 (6.7) | 3 (3.9) | 0.53 |
| G | 209 (95.9) | 73 (89) | 209 (93.3) | 73 (96.1) |

*p values are from χ² test

Table 4  Results of multiple linear regression analysis associated with SS values with adjustment for generally known cardiovascular risk factors and ER2 gene polymorphisms (rs1256049 and rs4986938)

| Independent variables | Women (n = 38) | Men (n = 110) | 95% C.I | 95% C.I |
|-----------------------|----------------|--------------|--------|--------|
| Age                   | 0.17           | (−0.25, 0.77) | 0.07   | (−0.14, 0.26) |
| GFR (MDRD)            | 0.33           | (−0.01, 0.33) | 0.03   | (−0.06, 0.09) |
| BUN                   | 0.45           | (0.15, 1.24)  | 0.14   | (−0.06, 0.64) |
| DM                    | −0.19          | (−12.29, 2.12)| −0.02  | (−4.30, 3.47) |
| Hypertension          | −0.09          | (−12.82, 7.71)| −0.11  | (−5.98, 1.34) |
| Hyperlipidemia        | 0.16           | (−3.09, 11.97)| 0.14   | (−0.74, 6.93) |
| Smoking               | 0.42           | (−10.97, 14.73)| 0.09 | (−1.45, 5.43) |
| Number of diseased vessels | 0.30 | (−2.87, 12.72) | 0.36 | (2.39, 7.82) |
| MVD                   | −0.38          | (−23.63, 2.9) | −0.19 | (−8.39, 0.26) |
| Sever CAD             | 0.14           | (−17.55, 7.53) | −0.14 | (−8.69, 0.91) |
| rs1256049             |               | | | |
| AA (reference)        | NA             | | | |
| AG                    | −0.14          | (−22.25, 7.97) | −0.02 | (−18.51, 17.40) |
| rs4986938             |               | | | |
| AA (reference)        | NA             | | | |
| AG                    | −0.09          | (−17.00, 12.00)| 0.27 | (0.08, 12.21) |
| GG                    | −0.17          | (−19.17, 9.73) | 0.28 | (0.02, 12.15) |

GFR glomerular filtration rate, BUN blood urea nitrogen, DM diabetes mellitus, CAD coronary artery disease, MVD multi-vessel disease, NA not assigned
Discussion
In this study the association between ER2 gene polymorphisms, rs1256049 and rs4986938, and SS was evaluated in 148 Iranian patients with CAD. About 75% of our cases was men. The same gender distribution was found in our previous investigation in patients undergoing elective PCI [10]. According to our results, CVD risk factors such as hypertension and active smoking were more prevalent in men compared to women. Higher frequency for history of smoking in men is completely predictable since smoking is not a common habit among Iranian women due to cultural issues. Unfortunately, it is in a growing manner in recent years. In contrast, older age and more cases with diseases such as diabetic mellitus and chronic kidney disease (CKD) were reported to be more prevalent in studied women than men. Older ages in studied women is congruent with the fact that women experienced CVD at higher ages than men. In addition, more rates of CKD involvement in women may be assumed due to higher rate of DM among women than men in this study.

Results of polymorphism analysis revealed that there was no significant association between rs4986938 gene polymorphism and their alleles with SS, on the other hand; a significant association was found between rs1256049 genotypes and SS. However, after performing the multivariate adjustment of confounding factors such as age, sex, incidence of hypertension, diabetes, smoking, etc., it was indicated that the value of SS may be decreased in studied men with the presence of GG and AG at rs4986938. This revealed the higher risk of CAD complexity as well as the worser PCI outcome in patients with rs4986938 GG and AG genotypes in comparison to AA genotype. In contrast, this association was not reported in women. This result may be related to the small sample size of women in our study.

Even though several researches evaluated the association between ER gene polymorphisms and CVD prognosis, most of them worked on ER1 gene polymorphisms [16–19] and only few evidences investigated the association between ER2 gene polymorphisms and CVD progress [20].

According to the available databases, our study is the first one evaluated the association between SS and SNPs of ER2 gene. A recently published case–control study performed on Chinese Han women population evaluated the association of SNPs of ER2 genes, rs1256049 and rs4986938, with CAD. Results of this study revealed that there was no significant association between the genotypes and/or haplotypes of these two SNPs and risk of CAD. Further subdivided age-based analysis in this study revealed significantly lower risk of CAD in AG genotypes of rs4986938 in comparison to homozygotes GG carriers in patients younger than 40 years of age. In contrast, homozygotes AA carriers had higher risk of CAD. They concluded that A allele of rs4986938 SNP would be an important predictor of CAD risk in Chinese women younger than 40 years of age. These correlations were not found in rs1256049 SNP [21]. Another case–control study on Brazilian population with premature CAD revealed a statistically significant association between rs4986938 SNP and CAD and it was introduced as one of the most important independent risk factors for CAD as well as dyslipidemia, elevated levels of triglycerides and apolipoprotein B and low levels of HDL in this research. The homozygote AA genotype was more prevalent in case group in comparison to control group [22]. Similar to these studies, our results showed a significant association between rs4986938 genotypes and CAD; however, with its complexity instead of its occurrence. Therefore, rs4986938 SNP may serve as an independent predictor of higher SS. However, a gender difference was reported regarding this association in different populations.

There are some other researches worked on other SNPs of ER2 gene such as rs1271572. A nested case–control study on Spanish population which was assessed the relationship between three SNPs of ER2 and myocardial infarction (MI) revealed that there was a significant association between rs1271572 SNP and enhanced risk of MI occurrence. This finding was limited to the men, therefore; this study suggested the potential role of gender in genetic variance of ER2 gene polymorphisms in MI patients [23]. Another study performed on American population confirmed a significant association between T allele of rs1271572 SNP and higher risk of MI and CVD, however; this association was just seen in women. Because of these controversial results on the association of ER2 polymorphisms and the risk of CVD occurrence and severity, further studies with larger sample sizes and assessments of patients with different ethnicities and genetics would be necessary [20].

The exact mechanism by which ER signaling and ER gene polymorphism play a role on CAD pathogenesis is uncertain. Recent studies revealed that estrogen could induce anti-fibrotic effects in the heart that would be occurred through the ER2 [2]. Results of an in vivo animal study revealed that activation of ER2 could stop the effects of angiotensin II (Ang-II) and endothelin-1 (ET-1) pro-fibrotic signaling thus prevent further cardiac fibrosis. Ang-II and ET-1 could induce cardiac fibrosis through the inversion of fibroblasts to myofibroblasts and also through the induction of transforming growth factor-β1 (TGFβ1) which is a known cardiac fibrosis inducer. Estrogen and ER2 agonists could stop TGFβ1 action via cAMP and protein kinase A pathway [3, 24]. Also previous studies revealed that estrogen administration could
enhance ER2 transcript expression which induces its anti-fibrotic effects [25]. It has been reported that ER2 gene overexpression would be a predictive factor for heart function improvement and survival in patients who had a recent history of MI both in men and women [26]. Results of another study on the role of ER1 and ER2 gene expression on the occurrence of neovascularization after ischemic heart disease revealed that both ER1 and ER2 (with the dominance of ER1) might have a pivotal role in estrogen-induced endothelial progenitor cells (EPCs) mobilization and further protection of cardiac function following a recent MI [27]. Another suggestive cardioprotective mechanism of ER2 gene would be through the induction of eNOS expression and further vasodilation in cases of ischemia/reperfusion (I/R) injury, especially in women [28]. These researches emphasizes the fact that in addition to the estrogen plasma level and the extent of ER1 and ER2 gene expression, evaluation of ER1 and ER2 genetic variance and polymorphisms would be helpful as predictive measures for identification of high risk patients for CVD and also their prognosis.

Because of the controversies around the role of ER2 SNPs in CVD in different populations, further larger investigations would be necessary in order to confirm our observed association between rs4986938 polymorphism and SS.

Study limitations
The possible limitations of our study were small sample size and unequal number of participants according to their gender (men and women). Also, it is suggested to evaluate the plasma estrogen levels of patients in combination with investigation of ER2 gene polymorphisms in future studies.

Conclusions
Besides to the estrogen level, the genetic variation of its receptors, ER1 and ER2, might play an important role in the pathogenesis, the severity and the complexity of CAD. According to our results, rs4986938 polymorphism of ER2 gene may assert a pivotal role in the severity of CAD in particular in men; however, this assumption needs to be proved in higher population studies.

Abbreviations
ER1: Estrogen receptor alpha; ER2: Estrogen receptor beta; SS: SYNTAX score; CVD: Cardiovascular disease; CAD: Coronary artery disease; CHD: Coronary heart disease; MVD: Multi-vessel disease; LMD: Left main coronary artery disease; MI: Myocardial infarction; CKD: Chronic kidney disease; DM: Diabetes mellitus; Ang-II: Angiotensin II; ET-1: Endothelin-1; TGFβ1: Transforming growth factor-β1; EPCs: Endothelial progenitor cells; ACE: Angiotensin converting enzyme; GFR: Glomerular filtration rate; MDRD: Modification of diet in renal disease; GPR30: G-protein-coupled estrogen receptor 30; SNP: Single nucleotide polymorphism; IMT: Intima-media thickness; LDL: Low density lipoprotein; PCR: Polymerase chain reaction.
disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017;8(1):1–16.
4. Xing D, Nozell S, Chen Y-F, Hage F, Oparil S. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol. 2009;29(3):289–95.
5. Wu MM, Hiseh YC, Lien LM, Chen WH, Bai CH, Chiu HC, et al. Association of estrogen receptor alpha genotypes/haplotypes with carotid intima-media thickness in Taiwanese women. Angiology. 2010;61(3):275–82.
6. Kunnas T, Silandker K, Karvanen J, Valkeapaa M, Salomaa V, Nikkari S. ESR1 genetic variants, haplotypes and the risk of coronary heart disease and ischemic stroke in the Finnish population: a prospective follow-up study. Atherosclerosis. 2010;211(1):200–2.
7. Demissie S, Cupples LA, Shearman AM, Gruenthal KM, Peter J, Schmid CH, et al. Estrogen receptor-alpha variants are associated with lipoprotein size distribution and particle levels in women: the Framingham Heart Study. Atherosclerosis. 2006;185(1):210–8.
8. Peter I, Kelley-Hedgepeth A, Huggins GS, Housman DE, Mendelssohn ME, Vita JA, et al. Association between arterial stiffness and variations in oestrogen-related genes. J Hum Hypertens. 2009;23(10):636–44.
9. Sianos G, Morel M-A, Kappetein AP, Morice M-C, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1(2):219–27.
10. Foroughinia F, Nouri BM, Kojuri J, Ostovan MA. Impact of omega-3 supplementation on high sensitive c-reactive protein level and 30-day major adverse cardiac events after the implementation of coronary stent in patients with chronic kidney disease: a randomized clinical study. Adv Pharm Bull. 2018;8(3):471.
11. Foroughinia F, Salamzadeh J, Namazi MH. Protection from procedural myocardial injury by omega-3 polyunsaturated fatty acids (PUFA s); is related with lower levels of creatine kinase-MB (CK-MB) and troponin I? Cardiovasc Ther. 2013;31(5):268–73.
12. [August 2020]. Available from: http://www.syntaxscore.com/
13. Kreatsoulas C, Natarajan M, Khatun R, Velianou J, Anand S. Identifying women with severe angiographic coronary disease. J Intern Med. 2010;268(1):66–74.
14. Tanaka T, Miki K, Akahori H, Imanaka T, Yoshihara N, Kimura T, et al. Comparison of coronary atherosclerotic disease burden between ST-elevation myocardial infarction and non-ST-elevation myocardial infarction. Non-culprit Gensini score and non-culprit SYNTAX score. Clinical Cardiology. 2020.
15. Ji-qiang H, Yue-chun G, Xian-peng Y, Xiao-ling Z, Ya-wei L, Chang-yan W, et al. Syntax score predicts clinical outcome in patients with three-vessel coronary artery disease undergoing percutaneous coronary intervention. Chin Med J. 2011;124(5):704–9.
16. Evangelopoulos D, Alevizaki M, Lekakis J, Cimponeriu A, Papamichael C, Kominakis A, et al. Molecular analysis of the estrogen receptor alpha gene in men with coronary artery disease: association with disease status. Clin Chim Acta. 2003;331(1–2):37–44.
17. Shearman AM, Cupples LA, Demissie S, Peter J, Schmid CH, Karas RH, et al. Association between estrogen receptor α gene variation and cardiovascular disease. JAMA. 2003;290(17):2263–70.
18. Casazza K, Page GP, Fernandez JR. The association between the rs2234693 and rs9340799 estrogen receptor α gene polymorphisms and risk factors for cardiovascular disease: a review. Biol Res Nurs. 2010;12(1):84–97.
19. Alevizaki M, Saltki K, Cimponeriu A, Kanakakis J, Xita N, Alevizaki C, et al. Severity of cardiovascular disease in postmenopausal women: associations with common estrogen receptor α polymorphic variants. Eur J Endocrinol. 2007;156(4):489–96.
20. Reworde KM, Rickmer PM, Hegener HH, Buring JE, Manson JE, Zee RY. Polymorphisms and haplotypes of the estrogen receptor β gene (ESR2) and cardiovascular disease in men and women. Clin Chem. 2007;53(10):1749–56.
21. Shen C, Chen Z, Mahmoodurrahman M, Chen X. Single nucleotide polymorphisms of ERβ and coronary atherosclerotic disease in Chinese Han women. Int J Clin Exp Pathol. 2015;8(2):2044.
22. de Padua MA, Nogueira CCM, Strunz CM, Aldrighi JM, Ramires JAF. Genetic polymorphisms of estrogen receptors in patients with premature coronary artery disease. Arch Med Res. 2005;36(5):511–7.
23. Domingues-Montanari S, Subirana I, Tomás M, Marrugat J, Sentí M. Association between ESR2 genetic variants and risk of myocardial infarction. Clin Chem. 2008;54(7):1183–9.
24. Pedram A, Razandi M, Narayanan L, Levin ER. Estrogen receptor beta signals to inhibition of cardiac fibrosis. Mol Cell Endocrinol. 2016;434.57–68.
25. Iorza A, Li J, Sharma S, Umar S, Bopassa JC, Nadadur RD, et al. Rescue of pressure overload-induced heart failure by estrogen therapy. Journal of the American Heart Association. 2016;5(1):e002482.
26. Schuster I, Mahmoodzadeh S, Dworatzek E, Jaiss F, Messaoudi S, Morano I, et al. Cardiomyocyte-specific overexpression of oestrogen receptor β improves survival and cardiac function after myocardial infarction in female and male mice. Clin Sci. 2016;130(S5):365–76.
27. Hamada H, Kim MK, Iwakura A, Ii M, Thorne T, Qin G, et al. Estrogen receptors α and β mediate contribution of bone marrow–derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation. 2006;114(21):2261–70.
28. Gabel SA, Walker VR, London RE, Steenbergen C, Korach KS, Murphy E. Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J Mol Cell Cardiol. 2005;38(2):289–97.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.